Led · Series B · Sep 2022

Elevation Spine is described in the filing as the leading innovator of integrated-fixation spinal technologies and markets a proprietary Saber® Technology platform. Its core product referenced in the article is the Saber-C® system. The company plans to use proceeds from its recent financing to ramp commercial production of Saber-C and to support product development of future Saber Technology extensions. Management said the funding will allow the company to build out a full commercial team and expand use of the Saber-C system. Investors and TVP leadership highlighted that Saber Technology allows surgeons to access hard-to-reach areas of the spine more easily and with fewer procedural steps. Elevation Spine directs readers to its website for more information.

Led · Series B · Aug 2022

Raven360 offers Digital Academies that let marketing teams embed knowledge-rich learning environments into their websites so prospects can research, demo and purchase products on their own terms. By aligning seller content with buyer problems from the first interaction, the platform turns web visitors into informed product evaluators and ultimately qualified leads. These academies generate predictive insights into each prospect’s stage in the buying journey, enabling marketing and sales teams to support buyer-led purchases more effectively. Fast-growing companies worldwide use Raven360 to onboard, teach, coach and inspire customers, partners and employees. With its newly raised capital, the company will expand sales and marketing, enhance the user experience and interface, and integrate machine-learning and AI capabilities to deepen engagement. Headquartered in Marlborough, Massachusetts, Raven360 positions itself as a critical tool in the modern CMO’s toolkit for creating top-of-funnel opportunities.

Participated · Series E · Oct 2021

RedShift BioAnalytics develops and commercializes a novel analytical platform, Microfluidic Modulation Spectroscopy (MMS), for detecting pivotal changes in molecular structure. Its flagship AQS3pro instrument delivers fully automated, ultrasensitive, and ultraprecise measurements of secondary structure for proteins, mRNA, AAVs, ADCs, mAbs, and other biomolecules. The company reports a rapidly growing list of user publications demonstrating broad utility across drug discovery, development, formulation, and quality control. RedShiftBio has sold instruments to the majority of leading biopharmaceutical companies in North America, Europe, and Asia. It recently opened the StructurIR Scientific Services Lab to provide institutions access for sample testing and proof-of-concept experiments. The company will use the new financing to fund additional commercial expansion, continue technology innovation, and execute product development objectives. Headquartered in Burlington, Massachusetts, RedShiftBio positions MMS as a tool for supporting biotherapeutics and vaccine development worldwide. RedShift BioAnalytics develops analytical instrumentation and a patented Microfluidic Modulation Spectroscopy (MMS) technique to probe protein secondary structure for biotherapeutic development. Its flagship AQS3pro infrared platform offers advanced data analytics and direct measurement of previously undetectable changes in protein structural attributes, replacing the need for multiple instruments. The company reports successful launch of the AQS3pro and installation of its first production systems at three major biopharmaceutical companies in the US and Europe. Management expects rapid commercial growth and has appointed Julien Bradley as CEO to lead expansion; Chip Marshall will remain as COO. RedShiftBio completed an oversubscribed $18M Series D Preferred Stock financing to support commercial expansion and continued innovation. The company targets improved decision-making across discovery, formulation and manufacture of protein therapeutics. RedShift BioAnalytics develops bioanalytical instruments for the R&D and manufacturing of protein-based therapeutics. Its platform combines innovative lasers, microfluidics and analytical technologies to deliver five critical measurements: quantitation, structure, stability, aggregation and similarity. The company is led by CEO Chip Marshall. In March 2017 it closed a financing to support commercialization efforts. RedShift says it will use the funds to accelerate commercialization of its biotechnology instrument platform in 2017. The business targets customers involved in protein therapeutic development and manufacturing. RedShift Systems develops infrared tunable filter technology, offering micro-optical tunable infrared filters that are solid-state devices with no moving parts. Its core products enable compact tunable components and systems for infrared spectroscopy. The company is entering the molecular spectroscopy market with a family of tunable infrared lasers that it says offer performance improvements over conventional FTIR-based solutions. RedShift intends to use new capital to increase adoption of its filters and lasers across existing and emerging infrared spectroscopy markets. The company is led by Chip Marshall (CEO) and Eugene Ma, Ph.D. (CTO and co-founder).

Led · Convertible Note · Apr 2021

Micrima has developed the MARIA® radio-wave breast scanning system, a non‑ionising, no‑compression imaging method intended to improve early breast cancer diagnosis. The company is at commercial stage with initial sales of its technology and distribution agreements in Germany, Austria and Switzerland through Hologic, Inc. A seventh-generation MARIA® system is planned for launch later this year, bringing improved accuracy, ergonomics and a new density‑scoring functionality. Management says the device has proven effective at accurately identifying cancer in diagnostic clinic trials and performs well in dense tissue versus the gold standard. The recent financing is intended to fund the next stage of product development, commercialisation and resumption of clinical data collection. Leadership also plans to work on automated classification of findings using the system's rich dataset. Micrima develops MARIA, a patented, CE-marked radiowave breast imaging system intended as an alternative to mammography. The system uses harmless radio-waves and requires no breast compression, and has been trialled in over 400 women in the UK. Trials at leading European centres are about to commence and the technology has proven effective in dense tissue. The company plans to move MARIA into full commercial launch later in 2018 and to expand the team with strategic hires. Micrima is led by Executive Chairman Roy Johnson and is based in Bristol, UK. The company recently raised additional equity to support product development and commercialization. Micrima is a Bristol, UK–based breast imaging company that has developed a CE Mark–approved radiowave imaging technology. The company’s core product is the MARIA system, which aims to make breast screening safer, more comfortable and more accessible. Micrima closed a £2.6m funding round to accelerate development and begin commercialization toward the end of this year. Backers in the round included Technology Venture Partners LLP, Swarraton Partners and the University of Bristol Enterprise Fund. The company is advancing a second version of the MARIA system due early next year, which will offer enhanced functionality including the ability to automatically distinguish between different types of lesion. Micrima is led by Executive Chairman Roy Johnson. Micrima develops a radiowave radar medical imaging system aimed at improving breast cancer detection. The company is led by executive chairman Roy Johnson and is based in Bristol, UK. It raised a further £600k in funding to advance the imaging system’s performance and validation. Proceeds will fund targeted performance improvements, the collection of validating clinical data at Bristol’s Southmead Hospital, hires for product development, and early work toward regulatory approval. Micrima’s primary interest is providing the first truly alternative breast‑cancer screening modality in decades. The firm had previously raised £900k in April 2012.

Led · Series A · Feb 2021

Ampion provides a revenue-management software platform for Community Solar and other distributed generation assets, covering subscriber acquisition, billing, payment and sustainability reporting. The company manages hundreds of megawatts of CDG assets and serves residential, commercial and anchor customers. Ampion’s platform targets enterprise CDG asset owners and professional operators seeking compliant acquisition and long-term revenue management. The company plans to expand its subscriber acquisition organization and increase investment in its revenue-management software. The Series A financing is intended to support the company’s accelerating growth amid strong market momentum in distributed renewable energy. Ampion emphasizes an enterprise-technology mindset to support clients expanding aggressively in the CDG market.